

DORSET MEDICINES ADVISORY GROUP

COMMISSIONING STATEMENT ON THE USE OF ELUXADOLINE FOR TREATING IRRITABLE BOWEL SYNDROME WITH DIARRHOEA FOR ADULTS.

SUMMARY	
<i>NHS Dorset Clinical Commissioning Group commissions, in accordance with NICE TA471, eluxadoline for treating irritable bowel syndrome with diarrhoea for adults whose condition has not responded to other currently available treatments, or when these treatments are contraindicated or not tolerated.</i>	
BACKGROUND	<p>The most common symptoms of Irritable Bowel Syndrome with Diarrhoea (IBS-D) are urgency and abdominal pain. The unpredictable nature of symptoms can cause anxiety and affect daily activities such as travelling. The symptoms can change over time and in severity affecting a patient's quality of life. Eluxadoline is a new treatment option to treat IBS-D.</p> <p>Eluxadoline (Truberzi®, Allergan) is an opioid receptor agonist and delta-opioid receptor antagonist that binds to opioid receptors in the digestive system and slows down the movement of food through the gut.</p> <p>Eluxadoline is recommended as an option for treating irritable bowel syndrome with diarrhoea in adults, only if:</p> <ul style="list-style-type: none">• The condition has not responded to other pharmacological treatments (for example, anti-motility agents, anti-spasmodics, tricyclic antidepressants) or• Pharmacological treatments are contraindicated or not tolerated, and it is started in secondary care.
RELEVANT NICE GUIDANCE	https://www.nice.org.uk/guidance/ta471
FORMULARY STATUS	Red
PBR STATUS	Drug cost within PbR Tariff
COMMISSIONING IMPLICATIONS	As per the NICE TA eluxadoline should be started in secondary, rather than primary care
RELEVANT CLINICAL COMMISSIONING PROGRAMME	Planned and Specialist Clinical Commissioning Group
PATIENT PATHWAY IMPLICATIONS	Not applicable
PRESCRIBING INFORMATION	<p>The recommended dose is 200 mg daily (one 100 mg tablet, twice daily).</p> <p>The tablets should be taken with food in the morning and in the evening.</p> <p>For patients who are unable to tolerate the 200 mg daily dose (one 100 mg tablet, twice daily), the dose can be lowered to 150 mg daily (one 75 mg tablet twice daily).</p>

	<p>In principle, general dose recommendations also apply to patients aged 65 years and above. However, given the potential for increased sensitivity to experience undesirable effects, it may be considered to initiate eluxadoline treatment in a dosage of 150 mg daily (one 75 mg tablet twice daily). If this dosage is well tolerated, but not sufficiently effective, dosage may subsequently be increased to 200 mg daily (one 100 mg tablet twice daily).</p> <p>Stop eluxadoline at 4 weeks if there is inadequate relief of the symptoms of irritable bowel syndrome with diarrhoea.</p> <p>The safety and pharmacokinetics of eluxadoline in patients with renal impairment have not yet been established. With the renal route being a minor route of elimination for eluxadoline, no dose adjustment based on renal function may be necessary.</p> <p>The safety and efficacy of eluxadoline in children aged 0 to 18 years have not yet been established.</p> <p>The most common adverse reactions with eluxadoline are gastrointestinal, including nausea, constipation and abdominal pain. For full details of adverse reactions and contraindications, see the Summary of Product Characteristics (SPC).</p> <p>▼ This medicinal product is subject to additional monitoring.</p>
SUMMARY OF EVIDENCE TO SUPPORT FORMULARY STATUS	<p>https://www.nice.org.uk/guidance/ta471</p> <p>irritable bowel syndrome in adults: diagnosis and management</p> <p>https://www.medicines.org.uk/emc/medicine/33178</p>
ASSESSMENT OF COST IMPLICATIONS	<p>Eluxadoline (Truberzi®) 75 mg film-coated tablets X 56 £88.20</p> <p>Eluxadoline (Truberzi®) 100 mg film-coated tablets X 56 £88.20</p> <p>Costs may vary in different settings because of negotiated procurement discounts.</p> <p>The NICE resource impact report states the cost from year 2021/22 once steady uptake is reached, is equivalent to £11,300 per 100,000 population.</p>
REFERENCES	<p>https://www.nice.org.uk/guidance/ta471</p>
DATE	August 2017
REVIEW DATE	August 2019 or before, in light of new information
CONTACT FOR THIS POLICY	<p>Vanessa Sherwood, Senior Pharmacist, NHS Dorset CCG</p> <p>Sarah Sanderson, Locality Pharmacist, NHS Dorset CCG</p>